Browse by intervention

ZenoWell taVNS: what it changed, and what it did not

One intervention, every measured benefit and result that did not improve in Issue 01. See who it moved for, where it stayed neutral or went the other way, and the next hypothesis Phoenix can validate.

Research issue
Issue 01
Data through
2026-08-09
Evidence map version
v1.1.0

How to read this

Phoenix research is longitudinal and observational: we follow real APOE4 carriers over time and compare each member with their own earlier self, with no placebo group, no randomisation, and members choosing their own interventions.

That means these are strong signals pointing at what to test next, not proof of cause. Most nutrition, supplement and lifestyle research you read online has exactly the same design. The difference is that we say so, and we show you the confounders.

Read the full methods and limits

What the Phoenix community is measuring

Browse exact outcomes and interventions. Each result keeps its source, measurement rule and audit record beside the claim.

ZenoWell taVNS evidence dossier

Evidence collected through 2026-08-09.

Most promising

Deep plus REM sleep

Verified wearable deep and REM sleep stages · Aim: higher

ZenoWell taVNS

Repeated positive

Two curated ZenoWell cases carried 44 and 23 more deep-plus-REM minutes on use nights; five of 40 study members had valid wearable coverage.

Selected member cases

  1. Current Convert · APOE4/4 · female · age 60-69

    Use nights carried 44 more deep plus REM minutes across 60 use and 91 non-use nights.

    What else changed: no nearby starts were recorded.

    Next study: repeat Deep plus REM sleep after a dated ZenoWell taVNS window.

  2. Signal Seeker · APOE3/4 · female · age 50-59

    Use nights carried 23 more deep plus REM minutes across 77 total nights.

    What else changed: no nearby starts were recorded.

    Next study: repeat Deep plus REM sleep after a dated ZenoWell taVNS window.

2 selected member cases · not a response rate

Logged members
40
Members with repeats
5
Observations
2
Nights
228
Measurements
228
Sources and context

Device-study members with real wearable data on logged use and non-use nights; placeholder rows are excluded.

  • report-lines-414-430, reviewed by independent verifier

2 selected cases shown with this evidence.

Heart-rate variability

Verified wearable heart-rate variability · Aim: higher

ZenoWell taVNS

Positive individual result

The Current Convert's heart-rate variability was 3% higher on ZenoWell use nights after more data resolved July's opposite direction.

Selected member cases

  1. Current Convert · APOE4/4 · female · age 60-69

    Heart-rate variability was 3% higher on use nights after the larger evidence window resolved July's opposite direction.

    What else changed: no nearby starts were recorded.

    Next study: repeat Heart-rate variability after a dated ZenoWell taVNS window.

1 selected member case · not a response rate

Logged members
40
Members with repeats
5
Observations
1
Sources and context

Device-study members with real wearable HRV on logged use and non-use nights.

  • report-lines-414-430, reviewed by independent verifier

1 selected case shown with this evidence.

Total sleep duration

Verified wearable total sleep duration · Aim: higher

ZenoWell taVNS

Positive individual result

The Signal Seeker averaged 522 total sleep minutes on use nights versus 494 on comparison nights across 77 nights.

Selected member cases

  1. Signal Seeker · APOE3/4 · female · age 50-59

    Use nights averaged 522 total sleep minutes versus 494 on comparison nights across 77 nights.

    What else changed: no nearby starts were recorded.

    Next study: repeat Total sleep duration after a dated ZenoWell taVNS window.

1 selected member case · not a response rate

Logged members
40
Members with repeats
5
Observations
1
Nights
77
Measurements
77
Sources and context

Device-study members with real wearable total sleep on logged use and non-use nights.

  • report-lines-414-430, reviewed by independent verifier

1 selected case shown with this evidence.

Keep the map

Take every result into your next experiment.

Get the Issue 01 Evidence Map by email. It groups the same evidence by outcome and by intervention, including what worked, what did not, and what Phoenix wants to test next.

Instant PDF · Issue 02 lands in your inbox the day it publishes · No spam

Turn evidence into your next test

Magnesium and homocysteine is 7 members from an answer.

Forty carriers with a dated start and a repeat blood test close it. Creatine, vitamin D3 and B12 sit further back. Your next blood test is somebody else's answer, and theirs is yours.

Take the 7-minute assessment